Actavis' agreement to buy Allergan for $66 billion put then-Allergan CEO David Pyott in line for a hefty payout in cash and shares--and now that the tie-up is official, he's collecting.
CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.
Thanks to deals signed on Monday alone, another $17 billion is set to change hands in the hyperacquisitive drug business, a single-day record that closes out a bracing quarter for buyouts. But with industry titans paying ever-higher prices for a shrinking number of assets, how long can the good times roll?
Quest Diagnostics is partnering with contract research organization Quintiles to create a joint venture to provide a range of clinical trial services to biopharmas including laboratory testing and patient recruitment and retention as well as development and commercialization of companion diagnostics.
Abbott Laboratories is selling off one-third of the stake in Mylan it acquired through last year's stock swap, a few weeks after Mylan wrapped up its $5.3 billion buyout of Abbott's portfolio of specialty and branded drugs.
Royal Philips disclosed a deal to sell off 80.1% of its interest in its LED component and Automotive lighting business for $2.8 billion with an additional contingent payment for up to $100 million. This deal will free up cash for Philips to invest in HealthTech, which combines its healthcare and consumer groups.
Fujifilm has dipped into its multibillion-dollar cache of buyout cash for the $307 million it needed to acquire Cellular Dynamics International, one of the pioneers in the stem cell research business.
Sanofi Chairman Serge Weinberg says his company can do without dealmaking. And good thing, Weinberg told Les Echos--because the potential buys on the market are too expensive.
Teva has been sitting on the sidelines for more than a year as its peers jumped head-first into a biopharma deal bonanza. But no longer: The Israeli company struck a $3.2 billion agreement to buy Auspex Pharmaceuticals, which will finally put it back onto the M&A map. And it's zeroing in on more deal targets, analysts say.
The European Commission is concerned that the $13.4 billion acquisition of Biomet by Zimmer will result in price increases due to reduced competition in orthopedic implants in the European Economic Area. In order to allay these fears, Zimmer has agreed to divest three businesses in specific European markets.